View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
June 9, 2021

Bayer studies cell and gene therapies for Parkinson’s disease

Bayer’s cell and gene therapy candidates are currently being analysed in Phase I clinical trials for Parkinson’s.

Bayer subsidiary BlueRock Therapeutics has dosed the first subject in an open-label Phase I clinical study of its pluripotent stem cell-derived dopaminergic neurons, DA01, to treat Parkinson’s disease.

A neurodegenerative movement disorder, Parkinson’s disease arises due to damage of nerve cells in the brain. It is known to affect more than ten million people globally.

BlueRock plans to leverage dopaminergic neurons to re-innervate the affected brain areas and reverse the degeneration process for possible restoration of motor function.

The Phase I trial will include ten subjects enrolled at sites in the US and Canada.

Participants will undergo a procedure to transplant dopamine-producing cells into the putamen, which is a deep brain structure impacted by Parkinson’s disease.

Evaluating the safety and tolerability of DA01 cell transplantation a year after transplant will be the trial’s primary goal.

The indication of transplanted cell survival and motor effects at one and two years after transplant will be included as secondary goals, along with continued safety and tolerability at two years and transplantation feasibility.

Parallelly, Bayer’s clinical-stage adeno-associated virus (AAV) gene therapy company, Asklepios BioPharmaceutical (AskBio), is developing a gene therapy programme that could potentially offer advanced treatments for Parkinson’s disease.

AskBio’s therapy leverages an AAV to carry the human glial cell line-derived neurotrophic factor (GDNF) gene to the neurons in the putamen. This process causes GDNF protein expression and secretion in areas of the brain affected by the disease.

According to data from long-term experiments with AAV-GDNF in rodents as well as non-human primate models, consistent expression of GDNF demonstrated the ability to induce regeneration of midbrain neurons and substantial motor recovery.

At present, this gene therapy programme is being evaluated for safety and initial efficacy in a Phase Ib clinical study in the US.

This trial, which was initiated in August last year, has enrolled a total of ten subjects so far.

Bayer Cell and Gene Therapy head Wolfram Carius said: “The potential of BlueRock and AskBio’s clinical candidates to treat Parkinson’s disease could be immense.

“For the first time, it might be possible to stop and reverse this degenerative disease and truly help patients with their high unmet medical need.”

In October last year, Bayer reported that the Phase III CHRONOS-3 trial of Aliqopa plus rituximab to treat patients with relapsed indolent Non-Hodgkin’s Lymphoma met its primary endpoint.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper
img

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena